Neurocrine 10-Q: Q3 Revenue $1.12B, Net Income $206.5M; New VYKAT XR Generic Suit Filed
NBIX sits 20% above its 52-week low of $122.138.
Summary
Neurocrine's Q3 10-Q backs up the morning's earnings release with $1,122.7 million of revenue and $206.5 million of net income, and discloses a new Alvogen ANDA against VYKAT XR plus full Soleno purchase accounting.
Key Events · Earnings and Guidance · NBIX
-
Q3 Revenue Up 41% to $1.12B
Total revenues were $1,122.7 million versus $794.9 million a year earlier, with INGREZZA at $801.5 million, CRENESSITY at $210.8 million and VYKAT XR at $106.7 million.
-
Net Income Flat on Equity Mark
Net income was $206.5 million and diluted EPS $1.96, held back by a $52.3 million unrealized loss on equity investments; nine-month net income was $548.8 million, or $5.26 per diluted share.
-
Soleno Accounting Detailed
The $2,829.9 million Soleno deal added $2,237.8 million of VYKAT XR developed product rights amortized over 16 years, $494.6 million of goodwill and a $489.4 million deferred tax liability.
-
New VYKAT XR Patent Challenge
Alvogen filed an ANDA seeking a generic VYKAT XR; Neurocrine sued in October 2026, triggering a 30-month FDA approval stay alongside exclusivities expiring March 2028 and March 2032.
Analysis · NBIX · Life Sciences
The 10-Q confirms the Q3 beat already reported in this morning's 8-K, but it also adds the full financial picture and two items investors did not have. First, the Soleno purchase accounting: a $2.24 billion VYKAT XR intangible amortized over 16 years, plus $494.6 million of goodwill. Second, a new Alvogen ANDA challenging VYKAT XR patents, which triggered a 30-month FDA approval stay on top of exclusivities running to March 2028 and March 2032. Cash fell to $789.7 million from $2,543.4 million at year-end after the $2.4 billion net Soleno payment, but $677.4 million of nine-month operating cash flow and a fully undrawn $1.0 billion revolver cover the gap. The quarter itself was solid — revenue up 41% to $1,122.7 million and diluted EPS of $1.96 — though a $52.3 million unrealized loss on equity investments (Voyager) held net income roughly flat year over year.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NBIX was trading at $146.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.8B. The 52-week trading range was $122.14 to $186.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.